1. Volume 3, Issue 9, Pages e421-e430 (September 2016)
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial 
The Lancet HIV 
Volume 3, Issue 9, Pages e421-e430 (September 2016)
DOI: /S (16)
Copyright © 2016 The BREATHER (PENTA 16) Trial Group. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
*One participant was unable to attend the randomisation visit due to a traffic accident and another participant was excluded because of unreliable attendance.
The Lancet HIV 2016 3, e421-e430DOI: ( /S (16) )
Copyright © 2016 The BREATHER (PENTA 16) Trial Group. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2 Time to viral rebound
(A) Kaplan-Meier graph adjusted for stratification factors—time from randomisation to viral rebound (confirmed viral load ≥50 copies per mL). (B) Estimated difference in proportion of participants with viral rebound (two-sided 90% CI) between short cycle therapy and continuous therapy at week 48 for different analyses. *Difference in estimated probability of viral rebound, Kaplan-Meier methods, with adjustment for study stratification factors. †Difference in estimated probability of viral rebound, Kaplan-Meier methods. ‡With exact confidence intervals. §Kaplan-Meier methods, censoring individuals who violated the profile at that time, with adjustment for study stratification factors.
The Lancet HIV 2016 3, e421-e430DOI: ( /S (16) )
Copyright © 2016 The BREATHER (PENTA 16) Trial Group. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3 Proportion of days MEMS caps were opened
Data for 31 participants in the short cycle therapy group and 30 participants in the continuous treatment group (including 23 in each group with data to 48 weeks). MEMS=Medication Event Monitoring System.
The Lancet HIV 2016 3, e421-e430DOI: ( /S (16) )
Copyright © 2016 The BREATHER (PENTA 16) Trial Group. Open Access article distributed under the terms of CC BY Terms and Conditions